ResMed (RMD) Competitors $275.29 +1.79 (+0.65%) Closing price 07/25/2025 03:59 PM EasternExtended Trading$275.20 -0.09 (-0.03%) As of 07/25/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RMD vs. SYK, MDT, BDX, EW, IDXX, DXCM, STE, PODD, HOLX, and BAXShould you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Insulet (PODD), Hologic (HOLX), and Baxter International (BAX). These companies are all part of the "health care equipment" industry. ResMed vs. Its Competitors Stryker Medtronic Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories DexCom STERIS Insulet Hologic Baxter International ResMed (NYSE:RMD) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership. Do analysts recommend RMD or SYK? ResMed presently has a consensus price target of $263.00, suggesting a potential downside of 4.46%. Stryker has a consensus price target of $428.55, suggesting a potential upside of 6.25%. Given Stryker's stronger consensus rating and higher probable upside, analysts plainly believe Stryker is more favorable than ResMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ResMed 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.73Stryker 0 Sell rating(s) 4 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.79 Which has stronger earnings & valuation, RMD or SYK? Stryker has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioResMed$4.69B8.62$1.02B$8.9130.90Stryker$22.60B6.81$2.99B$7.4054.51 Is RMD or SYK a better dividend stock? ResMed pays an annual dividend of $2.12 per share and has a dividend yield of 0.8%. Stryker pays an annual dividend of $3.36 per share and has a dividend yield of 0.8%. ResMed pays out 23.8% of its earnings in the form of a dividend. Stryker pays out 45.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 13 consecutive years and Stryker has increased its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Does the media prefer RMD or SYK? In the previous week, Stryker had 22 more articles in the media than ResMed. MarketBeat recorded 38 mentions for Stryker and 16 mentions for ResMed. ResMed's average media sentiment score of 1.34 beat Stryker's score of 1.31 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 13 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stryker 31 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RMD or SYK more profitable? ResMed has a net margin of 26.15% compared to Stryker's net margin of 12.31%. ResMed's return on equity of 25.67% beat Stryker's return on equity.Company Net Margins Return on Equity Return on Assets ResMed26.15% 25.67% 18.59% Stryker 12.31%23.74%11.25% Which has more volatility & risk, RMD or SYK? ResMed has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Do insiders and institutionals hold more shares of RMD or SYK? 55.0% of ResMed shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.7% of ResMed shares are held by company insiders. Comparatively, 5.9% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryStryker beats ResMed on 12 of the 20 factors compared between the two stocks. Get ResMed News Delivered to You Automatically Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RMD vs. The Competition Export to ExcelMetricResMedMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$40.10B$10.55B$5.70B$21.11BDividend Yield0.78%2.00%4.60%3.60%P/E Ratio30.9017.0728.1028.44Price / Sales8.6229.18429.3858.68Price / Cash29.6423.0336.2222.92Price / Book8.313.698.664.69Net Income$1.02B$234.77M$3.25B$995.51M7 Day Performance6.85%6.32%4.22%1.65%1 Month Performance7.33%7.94%10.51%4.54%1 Year Performance39.71%-13.57%34.40%9.99% ResMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RMDResMed3.5213 of 5 stars$275.29+0.7%$263.00-4.5%+32.1%$40.10B$4.69B30.909,980Positive NewsUpcoming EarningsSYKStryker4.5365 of 5 stars$387.58-0.5%$428.55+10.6%+23.2%$147.94B$22.60B52.3853,000Positive NewsUpcoming EarningsMDTMedtronic4.6569 of 5 stars$89.76+0.2%$98.19+9.4%+18.5%$115.12B$33.54B24.8095,000Positive NewsBDXBecton, Dickinson and Company4.8276 of 5 stars$175.49-1.9%$219.22+24.9%-20.3%$50.30B$20.18B33.4974,000Positive NewsDividend AnnouncementInsider TradeEWEdwards Lifesciences4.3573 of 5 stars$76.57+0.1%$81.00+5.8%+33.9%$44.91B$5.44B10.9415,800Trending NewsEarnings ReportAnalyst ForecastGap UpIDXXIDEXX Laboratories3.5802 of 5 stars$520.87+1.2%$560.33+7.6%+20.1%$41.89B$3.90B48.1411,000Positive NewsDXCMDexCom4.7283 of 5 stars$84.03+0.2%$99.60+18.5%-17.5%$32.95B$4.03B62.7110,300Upcoming EarningsSTESTERIS4.7945 of 5 stars$222.55-1.3%$266.50+19.7%+1.6%$21.89B$5.46B35.9017,787Analyst ForecastPODDInsulet4.5952 of 5 stars$280.96-1.2%$321.00+14.3%+52.0%$19.77B$2.07B50.533,900Positive NewsHOLXHologic4.7313 of 5 stars$63.69-0.5%$77.33+21.4%-14.6%$14.19B$4.03B26.877,063Positive NewsUpcoming EarningsAnalyst RevisionBAXBaxter International4.3157 of 5 stars$27.40-1.3%$36.38+32.7%-16.7%$14.06B$10.77B-24.9138,000Upcoming Earnings Related Companies and Tools Related Companies Stryker Competitors Medtronic Competitors Becton, Dickinson and Company Competitors Edwards Lifesciences Competitors IDEXX Laboratories Competitors DexCom Competitors STERIS Competitors Insulet Competitors Hologic Competitors Baxter International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RMD) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ResMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ResMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.